These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17885205)

  • 1. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.
    Ceraudo E; Murail S; Tan YV; Lacapère JJ; Neumann JM; Couvineau A; Laburthe M
    Mol Endocrinol; 2008 Jan; 22(1):147-55. PubMed ID: 17885205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.
    Tan YV; Couvineau A; Murail S; Ceraudo E; Neumann JM; Lacapère JJ; Laburthe M
    J Biol Chem; 2006 May; 281(18):12792-8. PubMed ID: 16520374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
    Couvineau A; Tan YV; Ceraudo E; Lacapère JJ; Murail S; Neumann JM; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
    Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP.
    Tan YV; Couvineau A; Laburthe M
    J Biol Chem; 2004 Sep; 279(37):38889-94. PubMed ID: 15247290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.
    Ceraudo E; Tan YV; Nicole P; Couvineau A; Laburthe M
    J Mol Neurosci; 2008 Nov; 36(1-3):245-8. PubMed ID: 18597186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
    Tan YV; Couvineau A; Lacapere JJ; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VPAC1 receptor binding site: contribution of photoaffinity labeling approach.
    Couvineau A; Ceraudo E; Tan YV; Laburthe M
    Neuropeptides; 2010 Apr; 44(2):127-32. PubMed ID: 20031208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
    Tan YV; Couvineau A; Van Rampelbergh J; Laburthe M
    J Biol Chem; 2003 Sep; 278(38):36531-6. PubMed ID: 12807902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.
    Ceraudo E; Hierso R; Tan YV; Murail S; Rouyer-Fessard C; Nicole P; Robert JC; Jamin N; Neumann JM; Robberecht P; Laburthe M; Couvineau A
    FASEB J; 2012 May; 26(5):2060-71. PubMed ID: 22291440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.
    Couvineau A; Tan YV; Ceraudo E; Laburthe M
    Methods Enzymol; 2013; 520():219-37. PubMed ID: 23332702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor.
    Couvineau A; Robert JC; Ramdani T; Lacapère JJ; Rouyer-Fessard C; Laburthe M
    J Mol Neurosci; 2008 Nov; 36(1-3):249-53. PubMed ID: 18592417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.
    Couvineau A; Laburthe M
    Br J Pharmacol; 2012 May; 166(1):42-50. PubMed ID: 21951273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
    J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human VPAC1 receptor: three-dimensional model and mutagenesis of the N-terminal domain.
    Lins L; Couvineau A; Rouyer-Fessard C; Nicole P; Maoret JJ; Benhamed M; Brasseur R; Thomas A; Laburthe M
    J Biol Chem; 2001 Mar; 276(13):10153-60. PubMed ID: 11124960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
    Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
    Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
    Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
    de Maria S; Metafora V; Metafora S; Ravagnan G; Cartení M; Pontoni G; Facchiano A; Lepretti M; Severino B; Caliendo G; Santagada V; Langer I; Robberecht P
    J Pept Sci; 2008 Jan; 14(1):102-9. PubMed ID: 17883247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.